Literature DB >> 18172842

Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates.

Ramesh R Kale1, Colleen M McGannon, Cynthia Fuller-Schaefer, Duane M Hatch, Michael J Flagler, Shantini D Gamage, Alison A Weiss, Suri S Iyer.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18172842     DOI： 10.1002/anie.200703680

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  14 in total

1.  In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.

Authors:  Pavel I Kitov; George L Mulvey; Thomas P Griener; Tomasz Lipinski; Dmitry Solomon; Eugenia Paszkiewicz; Jared M Jacobson; Joanna M Sadowska; Missao Suzuki; Ken-Ichi Yamamura; Glen D Armstrong; David R Bundle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

2.  Chemical Synthesis of a Glycopeptide Derived from Skp1 for Probing Protein Specific Glycosylation.

Authors:  Zoeisha S Chinoy; Christopher M Schafer; Christopher M West; Geert-Jan Boons
Journal:  Chemistry       Date:  2015-07-15       Impact factor: 5.236

Review 3.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

4.  Different classes of antibiotics differentially influence shiga toxin production.

Authors:  Colleen Marie McGannon; Cynthia Ann Fuller; Alison Ann Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

6.  Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2.

Authors:  Ashish A Kulkarni; Cynthia Fuller; Henry Korman; Alison A Weiss; Suri S Iyer
Journal:  Bioconjug Chem       Date:  2010-08-18       Impact factor: 4.774

7.  Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.

Authors:  Michael J Flagler; Sujit S Mahajan; Ashish A Kulkarni; Suri S Iyer; Alison A Weiss
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

8.  Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.

Authors:  Hailemichael O Yosief; Suri S Iyer; Alison A Weiss
Journal:  Infect Immun       Date:  2013-05-20       Impact factor: 3.441

9.  Capture of uropathogenic E. coli by using synthetic glycan ligands specific for the pap-pilus.

Authors:  Hailemichael O Yosief; Alison A Weiss; Suri S Iyer
Journal:  Chembiochem       Date:  2013-01-10       Impact factor: 3.164

10.  The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.

Authors:  Jared M Jacobson; Jiang Yin; Pavel I Kitov; George Mulvey; Tom P Griener; Michael N G James; Glen Armstrong; David R Bundle
Journal:  J Biol Chem       Date:  2013-11-13       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.